tiprankstipranks
Advertisement
Advertisement
Ascendis Pharma Earnings Call Highlights Growth Momentum
PremiumCompany AnnouncementsAscendis Pharma Earnings Call Highlights Growth Momentum
20d ago
Ascendis Pharma price target lowered to $326 from $330 at Wells Fargo
Premium
The Fly
Ascendis Pharma price target lowered to $326 from $330 at Wells Fargo
23d ago
Analyst Reiterates Buy on Robust Rare Endocrine Portfolio and Pipeline Progress as Price Target Nudged to $288 on Higher Share Count
Premium
Ratings
Analyst Reiterates Buy on Robust Rare Endocrine Portfolio and Pipeline Progress as Price Target Nudged to $288 on Higher Share Count
23d ago
Ascendis Pharma Updates ISIN for Nasdaq-Listed Ordinary Shares
PremiumCompany AnnouncementsAscendis Pharma Updates ISIN for Nasdaq-Listed Ordinary Shares
1M ago
Ascendis Pharma Completes ADS-to-Ordinary Share Conversion and Begins Direct Nasdaq Trading
Premium
Company Announcements
Ascendis Pharma Completes ADS-to-Ordinary Share Conversion and Begins Direct Nasdaq Trading
1M ago
Ascendis Pharma announces commencement of trading of shares on Nasdaq
Premium
The Fly
Ascendis Pharma announces commencement of trading of shares on Nasdaq
1M ago
Ascendis Pharma Reports Strong Week 52 COACH Trial Data for TransCon CNP and hGH Combo in Achondroplasia
PremiumCompany AnnouncementsAscendis Pharma Reports Strong Week 52 COACH Trial Data for TransCon CNP and hGH Combo in Achondroplasia
2M ago
Ascendis Pharma to Replace ADSs With Direct Ordinary Share Listing on Nasdaq
Premium
Company Announcements
Ascendis Pharma to Replace ADSs With Direct Ordinary Share Listing on Nasdaq
2M ago
Ascendis Pharma to list ordinary shares directly on Nasdaq
Premium
The Fly
Ascendis Pharma to list ordinary shares directly on Nasdaq
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100